New Zealand markets closed

BIIB Jun 2024 195.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
13.55+2.65 (+24.31%)
As of 01:48PM EDT. Market open.
Full screen
Loading interactive chart…
  • Yahoo Finance Video

    Biogen stock rises on Q1 results, Alzheimer's drug sales

    Shares of the biopharmaceutical company Biogen (BIIB) are on the rise Wednesday, buoyed by the company's first quarter results. The company beat profit expectations, driven by Biogen's cost-cutting initiatives and the boost in sales for its Alzheimer's drug, Leqembi. Yahoo Finance's Anjalee Khemlani breaks down the details of the report. For more expert insight and the latest market action, click here to watch this full episode of Morning Brief. This post was written by Angel Smith

  • Investor's Business Daily

    Biogen Stock Surges After Two Notable Products Walloped Sales Expectations

    Two of Biogen's newest drugs walloped first-quarter sales expectations on Wednesday, and helped Biogen stock jump.

  • Zacks

    Biogen (BIIB) Q1 Earnings Beat, Stock Up on Alzheimer Drug Uptake

    Biogen's (BIIB) first-quarter earnings beat estimates but sales miss the mark. While sales of key drugs like Tecfidera, Tysabri & Spinraza declined, the company's cost-saving efforts show promise.